José Ignacio Andrés-Gil

USPTO Granted Patents = 39 (Patent Applications = 11)

CIPO Patents = 15 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 50(Granted Patents)

Location History:

Toledo, ES (2013 - 2020)
Madrid, ES (1997 - 2024)

Company Filing History:

34 out of 2,078

Janssen Pharmaceutica Nv

patents

3 out of 1,155

Vanderbilt University

patents

2 out of 159

Janssen Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 1997-2024

Loading Chart...

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12006302 - Tau PET imaging ligands (2024-06-11),

2. 11168068 - Tau PET imaging ligands (2021-11-09),

3. 11045562 - Radiolabelled mGluR2/3 PET ligands (2021-06-29),

4. 11033641 - Radiolabelled mGluR2/3 pet ligands (2021-06-15),

5. 10967078 - Radiolabelled mGluR2 PET ligands (2021-04-06),

6. 10604523 - 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives (2020-03-31),

7. 10584129 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors (2020-03-10),

8. 10519162 - 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors (2019-12-31),

9. 10512646 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors (2019-12-24),

10. 10112949 - 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors (2018-10-30),

11. 10106542 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors (2018-10-23),

12. 10005786 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of MGLUR2 receptors (2018-06-26),

13. 10005785 - Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors (2018-06-26),

14. 9669035 - Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders (2017-06-06),

15. 9266834 - 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors (2016-02-23),

Title: **José Ignacio Andrés-Gil: Innovator in Tau PET Imaging Ligands**

Introduction

José Ignacio Andrés-Gil, based in Madrid, Spain, is an accomplished inventor with a prolific portfolio of 29 patents. His innovations primarily focus on developing novel, selective radiolabelled tau ligands that significantly enhance the field of medical imaging.

Latest Patents

Among his notable inventions are several patents related to Tau PET imaging ligands. These inventions contribute to the advancement of imaging and quantifying tau aggregates through positron-emission tomography (PET). The patents also cover compositions comprising such compounds, processes for their preparation, and applications for imaging tissues or subjects, both in vitro and in vivo. This innovative work holds considerable promise for improving diagnostic techniques in neurology.

Career Highlights

Throughout his career, José has held positions at esteemed institutions, including Janssen Pharmaceutica NV and Vanderbilt University. His work in these organizations has played a pivotal role in advancing research and fostering innovation in medical imaging technologies.

Collaborations

José has collaborated with several distinguished colleagues, such as Manuel Jesús Alcázar-Vaca and Michiel Luc Maria Van Gool. These partnerships have enhanced the research and development of his groundbreaking patents, reflecting the importance of teamwork in achieving scientific advancement.

Conclusion

In conclusion, José Ignacio Andrés-Gil stands out as an influential figure in the field of biotechnology and medical imaging. His contributions through innovative patents and collaborations are invaluable to the ongoing advancement of imaging techniques, potentially transforming diagnostic approaches for neurological conditions.

This text is generated by artificial intelligence and may not be accurate.